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Regulatory T cells (Tregs) are a subpopulation of CD4+ T cells with a fundamental
role in maintaining immune homeostasis and inhibiting unwanted immune responses
using several different mechanisms. Recently, the intercellular transfer of molecules
between Tregs and their target cells has been shown via trogocytosis and the release
of small extracellular vesicles (sEVs). In this study, CD4+CD25+CD127lo human Tregs
were found to produce sEVs capable of inhibiting the proliferation of effector T cells
(Teffs) in a dose dependent manner. These vesicles also modified the cytokine profile
of Teffs leading to an increase in the production of IL-4 and IL-10 whilst simultaneously
decreasing the levels of IL-6, IL-2, and IFNγ. MicroRNAs found enriched in the Treg EVs
were indirectly linked to the changes in the cytokine profile observed. In a humanized
mouse skin transplant model, human Treg derived EVs inhibited alloimmune-mediated
skin tissue damage by limiting immune cell infiltration. Taken together, Treg sEVs may
represent an exciting cell-free therapy to promote transplant survival.
Keywords: Regulatory T (Treg) cells, extracellular vesicles, cytokines, allograft rejection, miRNA – microRNA
INTRODUCTION
Regulatory T cells (Tregs) are essential for the maintenance of tolerance to self-antigens and
immune homeostasis (Shevach, 2018). In humans, a link between the frequency of Tregs within
allografts and longevity has been described (Pearce et al., 1993), whilst the adoptive transfer of
ex vivo expanded murine, or human Tregs, in preclinical murine transplant models significantly
prolonged the survival of murine and human skin allografts, respectively (Sagoo et al., 2011;
Abbreviations: Regulatory T cells (Tregs); Extracellular vesicles (EVs); Effector T cell (Teff) and Dendritic cells (DCs).
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Boardman et al., 2017; Pilat et al., 2019). Given their efficacy
in vivo, we are currently conducting Phase I/II clinical trials to
investigate the therapeutic potential of autologous Treg therapy
to promote transplant survival rates in kidney (The ONE Study:
NCT02129881) and liver (ThRIL: NCT02166177) transplant
recipient patients (Romano et al., 2017; Sánchez-Fueyo et al.,
2019). Despite being used in the clinical setting how these
cells function and their target cells in vivo have yet to be
clearly elucidated.
Tregs are a heterogeneous CD4+CD25+ T cell subpopulation
consisting of thymus derived (natural) and peripheral (induced)
Tregs which suppress other immune cells, such as effector T
cell (Teff) and dendritic cells (DCs) through both cell contact
dependent and independent mechanisms (Romano et al., 2019).
These include IL-2 deprivation through expression of CD25,
production of immune modifying cytokines such as TGFβ, IL-10
and IL-35, induction of target cell death and inhibition of
antigen presenting capacity of DCs [reviewed in Shevach (2009)].
Recently, Tregs were found to maintain immune homeostasis
through the intercellular acquisition, or trogocytosis, of key
components involved in activating Teffs. For example, Samson
and colleagues have shown that CTLA-4 expressed on Tregs
removed CD80/86 from the surface of antigen presenting cells
(APCs), thereby limiting their co-stimulatory capacity (Qureshi
et al., 2011). More recently, antigen-specific Tregs that formed
strong interactions with peptide pulsed DCs were shown to
remove MHC class II: peptide complexes from these cells,
reducing their capacity to present antigen (Akkaya et al., 2019).
Intercellular communication by Tregs has also been shown
to occur via the release of small extracellular vesicles (EVs).
CD4+CD25+ Tregs isolated from rodents [mouse (Smyth et al.,
2013; Okoye et al., 2014), and rat (Yu et al., 2013; Aiello et al.,
2017)] and humans (Torri et al., 2017; Azimi et al., 2018) were
found to produce EVs following TCR activation. These vesicles
displayed in vitro immune modulatory properties similar to
the cell they were derived from [Smyth et al. (2013), Okoye
et al. (2014), Torri et al. (2017)]. We have shown that exposure
to murine Treg EVs causes (i) a reduction in CD4+ Teff cell
proliferation as well as IL-2 and IFNγ release (Smyth et al.,
2013), and; (ii) an increase in IL-10 production by murine DCs
following LPS stimulation (Tung et al., 2018). We attributed
these effects to the cell surface immune modulatory molecule
CD73, an ecto enzyme involved in adenosine production (Smyth
et al., 2013), and specific miRNAs, such as miR-142 and miR-
150, present in these vesicles (Tung et al., 2018). Other miRNAs,
such as Let-7d and miR-146a-5p have also been linked to the
suppressive capacity of these vesicles (Okoye et al., 2014; Torri
et al., 2017). Treg-derived EVs have also been shown to transfer
iNOS to target cells as a means of disrupting signaling pathways
and eliciting a regulatory function (Aiello et al., 2017).
So far, only a few groups have studied the suppressive capacity
of Treg EVs in vivo in animal models of intestinal inflammation
and solid organ transplants. Adoptive transfer of Let-7d deficient
murine Tregs into Rag−/− mice reconstituted with CD45RBhi
cells failed to prevent intestinal inflammation compared to wild
type Tregs (Okoye et al., 2014). The authors demonstrated
in vitro that this outcome was due to a decreased suppressive
activity of Let-7d deficient Treg EVs compared to their untreated
counterparts (Okoye et al., 2014). In a rat transplant model,
Yu et al. (2013) demonstrated that the administration of Treg
vesicles post-transplant prolonged the survival time and function
of kidney grafts (Yu et al., 2013). More recently, Aiello et al.
(2017) observed that EVs derived from induced Tregs, generated
by co-culturing rat CD4+CD25− cells with DCs made immature
by inhibiting NF-KB, by overexpressing the dominant negative
form of IKK2, promoted transplant tolerance only when given in
combination with Cyclosporine (Aiello et al., 2017). From these
observations, it could be envisaged that like their cell counterpart,
human Treg EVs may represent a promising therapeutic tool for
treating transplant rejection or autoimmunity.
In this study, we investigated the mechanisms of action of
human Treg EVs and their function in vivo using an established
humanized mouse model of human skin transplantation. Our
results demonstrated the immune regulatory role of human Treg
EVs in vivo and highlighted the possibility of applying them to
prevent transplant rejection.
MATERIALS AND METHODS
Human CD4+CD25+ and CD4+CD25−
Isolation and Expansion
Anonymous healthy donor blood was obtained from the
National Blood Service (NHS Blood and Transplantation,
London, United Kingdom) with informed consent and ethical
approval (Institutional Review Board of Guy’s Hospital;
reference 09/H0707/86). RosetteSepTM (StemCell Technologies,
Cambridgeshire, United Kingdom) was used to select CD4+
T cells. Subsequently, CD25 Microbeads II (Miltenyi Biotec,
Surrey, United Kingdom) were used to separate CD4+CD25+
(Tregs, Supplementary Figures S1A,B,E) and CD4+CD25−
(Teffs, Supplementary Figures S1C,D) cells. Tregs were cultured
and expanded for 20 days as previously reported (Scottà et al.,
2013). Briefly, isolated Tregs were cultured in X-VIVO 15
medium (Lonza, Berkshire, United Kingdom) supplemented
with 5% heat-inactivated human AB serum (Biosera, Sussex,
United Kingdom) in the presence of anti-CD3/CD28-coated
beads (Thermo Fisher Scientific, Paisley, United Kingdom),
100 nM rapamycin (LC-Laboratories, MA, United States) and
1000 U/mL recombinant IL-2 (Proleukin-Novartis, Camberley,
Surrey, United Kingdom). Teffs were cultured in the same media
in the presence of anti-CD3/CD28-coated beads and 100 U/mL
recombinant IL-2. All cell cultures were tested for mycoplasma
and all samples used were mycoplasma free.
EV Purification and Quantitation
Anti-CD3/CD28 beads were removed from cultured cells using
a magnet and bead free Tregs and Teffs were cultured in
EV-free culture medium for 2 days in the presence of low
dose IL-2 (100 IU/ml) in the absence of rapamycin. EV-free
media consisted of X-VIVO 15 supplemented with 5% EV
free heat-inactivated fetal bovine serum (FBS; Thermo Fisher
Scientific). This media was subjected to ultracentrifugation for
18 h at 100,000 × g and 4◦C using a L8-60M Beckman
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FIGURE 1 | Activated human Tregs release EVs. (A) (1st panel) Representative EM image of EVs released by activated human Treg cells. Scale bar indicates
100 nm. 2nd panel, A representative of a size distribution plot for EVs released by TCR activated Tregs. The EV samples were acquired using the NanoSight
(Continued)
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FIGURE 1 | Continued
LM-10 and 5 videos of 30 s duration were recorded. Histogram represents the mean size from all 5 measurements with the red error bars indicating mean ± 1 SEM.
3rd panel, the average mean particle size and the average mode size of Treg EVs isolated from 12 individual donors. (B) Graph shows the number of EVs released
per cell from resting versus activated Tregs. EVs were isolated from Tregs expanded from 5 donors. (C) Representative flow cytometry histogram plots showing the
expression of CD63, CD81, CD25, CTLA4, CD39, CD73, Fas-Ligand, CD4, and CCR4 on Treg EVs attached to latex beads following specific antibody staining
(black lines). Control samples (gray lines) represent beads stained with the aforementioned antibodies in the absence of EVs. Values indicate the mean fluorescence
intensity (MFI) for each of the molecules shown and the control beads. Data represents 1 out of 3 independent experiments. (D) Left panel, graph showing the
average number of CD63+ EVs (×109) ± SEM detected from 1 × 106 Tregs isolated from 3 donors using a CD63 ExoELISA (left panel). Right panel, Western blot
showing CD63 (top panel), CD81 (middle panel) and Calnexin (lower panel) expression in Treg EVs lysates (2 individual donors) and Treg cell lysates (1 individual
donor). (E) Normalized Total Spectra of described proteins found in Treg EVs (1 individual donor).
Coulter ultracentrifuge with a Type 70.1 Ti rotor. To isolate
EVs, 5–50 × 106 T cells (2.5 × 106 per ml) were activated
using plate-bound anti-CD3 (5 mg/mL, OKT3; Thermo Fisher
Scientific) and anti-CD28 (10 mg/mL, αCD28.2) antibodies
in EV free media. 24 h post-activation, cell culture media
was collected and differential centrifugation preformed. Briefly,
culture supernatant was centrifuged at 300 g for 10 min, at
2000 g for 10 min and passed through a 0.22 µm pore-
sized filter (Merck Millipore, MA, United States). EVs were
isolated via ultracentrifugation or ExoQuick-TCTM (Systems
Biosciences, California, United States). ExoQuick-TCTM was
used according to manufacturer’s instructions. Alternatively,
EVs were pelleted at 100,000 g using a Beckman L8-60M
ultracentrifuge with Beckman Type 70.1 Ti rotor for 1.5 h at
4◦C. The EV enriched pellet was washed in PBS at 100,000 g for
1.5 h at 4◦C. Ultracentrifugation was employed for transmission
electron microscopy, NanoSight LM-10 (NanoSight, Malvern,
Kk) and flow cytometry EV analysis. EV enriched pellets were
re-suspended in PBS and used immediately except for NanoSight
LM-10 analysis where EVs were stored at−80◦C. EV isolation via
ExoQuick-TCTM was employed for EV RNA extraction, protein
analysis, EV suppression assays with subsequent cytokine bead
array analysis and for the in vivo experiments. EVs pellets derived
from ExoQuick-TCTM were re-suspended in EVs-free complete
media for in vitro analysis and sodium chloride (NaCl) 0.9% w/v
saline (B Braun, Sheffield, United Kingdom) for in vivo analysis.
To measure the concentration and size of the particles isolated,
EVs were assessed on a NanoSight LM10 under a constant flow
injection. 5 videos of 30 s duration were recorded per sample.
Electron Microscopy (EM)
10 × 106 Tregs were activated and EVs isolated as described
above. EVs were added to Formvar/carbon films with copper
grids (TAAB, United Kingdom) and following fixation with
2% glutaraldehyde (Sigma-Aldrich, Dorset, United Kingdom),
the grids were washed three times with distilled water. EVs
were then stained with 3% uranyl acetate (Sigma-Aldrich) and
2% methylcellulose and analyzed on a transmission electron
microscope (FEI TecnaiTM G2 20, Netherlands). All steps were
performed at room temperature.
Cell and EVs Phenotype
All antibodies were purchased from Thermo Fisher Scientific
unless otherwise stated and cells were stained using FACS buffer
(PBS containing 5 mM EDTA and 1% FCS). Cells were stained
with antibodies specific for human; CD4 (OK-T4), CD25 (AE3),
CD127 (eBioRDR5), FoxP3 (PCH101), CD39 (eBioA1), CD73
(AD2), CTLA4 (BN13), CD69 (H1.2F4), CD81 (5A6), CD9
(eBioSN4), CD63 (HSC6), TCRαβ (T1089.1A-31) and CCR4
(L291H4). Intracellular staining was performed using a FoxP3
staining buffer set according to manufacturer’s instructions. To
stain Treg EVs, EVs were coated onto 4 µm aldehyde/sulfate
latex beads (Thermo Fisher Scientific) before the addition of
fluorochrome-conjugated antibodies, as previously described
(Smyth et al., 2013). Cells and beads were acquired using BD
LSR-Fortessa flow cytometer (BD Biosciences, Franklin Lakes,
NJ, United States) and analyzed using FlowJo 10 software
(Tree Star, OR, United States). CD63 expression on Treg
EVs was also assessed using an ExoELISA-ULTRA complete
kit (CD63 detection), following manufacture’s instructions
(Systems Biosciences).
SDS Page Gel and Western Blotting
All reagents were purchased from Thermo Fisher Scientific,
unless otherwise stated. Treg EVs isolated from (50 × 106)
Tregs and Tregs (1 × 106) were lysed in RIPA buffer
supplemented with protease inhibitors (Merck, Gillingham,
United Kingdom). 10 µgs of denatured protein was run on a 10–
20% Novex WedgeWell Protein gel and proteins were transferred
onto a PVDF membrane. CD63 and CD81 were assessed
using an ExoAb antibody kit following the manufacture’s
instructions (Systems Biosciences). Calnexin expression
was assessed using a rabbit anti-human/mouse Calnexin
primary Ab (Proteintech, Manchester, United Kingdom)
followed by a goat anti-rabbit Ig-HRP conjugated secondary
Ab (Cell Signaling Technologies MA, United States), both
at a 1:1000 dilution. Protein bands were visualized using
ECL and a ChemiDoc Imaging System (Bio-Rad, Watford,
United Kingdom).
Mass Spectrometry
Treg EVs, isolated using ExoQuick-TC, were sent for
proteomic analysis at Systems Biosciences (SBI Exosome
Proteomics Services) and a total EV protein prolife was
undertaken. Briefly, according to SBI, EVs were lysed
using a sonic probe and 10 µg of sample run on a 10%
Bis Tris NuPage gel. An in gel-based digestion, using
trypsin, was undertaken to generate peptidic libraries for
nano LC-MS/MS analysis using a Waters NanoAcquity
HPLC system. Data analysis was undertaken using Scaffold
Proteome Software.
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FIGURE 2 | Human Treg EVs are suppressive. (A) 1 × 105 Cell Trace Violet (CTV) CD4+25- (Teffs) were co-cultured alone (Top left panel, Resting Teffs) or with
anti-CD3/CD28 coated beads, in the absence (Top right panel, Activated Teffs) or presence of Treg EVs derived from various numbers of Tregs (Lower panels, + Treg
EVs). After 5 days the proliferation of the CTV Teffs was assessed by flow cytometry. Representative data of the percentage proliferation from an individual donor is
(Continued)
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FIGURE 2 | Continued
shown. (B) Average% suppression of Teff proliferation following exposure to increasing dose of Treg EVs. Data is from 3 independent experiments using 3 individual
donors. Bars show mean + SEM. (C) Graph represents the% suppression of Teffs from at least 7–9 independent donors, each shown as an individual point,
following co-culture with various ratios of Treg cells or Treg EVs derived from 50 × 106 Treg cells. The mean ± SEM is shown. In all panels data are expressed as
percentage of suppression of Teff proliferation relative to Teffs cultured alone with anti-CD3/28 beads. (D) Teffs were activated with anti-CD3/28 beads for 5 days in
the absence (Activated Teffs) or presence of proteins and EVs isolated from culture media (Activated Teffs + media pellet). Flow cytometry histogram plots represent
the proliferation of Teffs as measured by CTV dilution. Data shown represents one of 6 individual experiments with the pooled percentage CFSE−/lo cells
(% proliferation) shown in the right panel. Statistical significance was tested using one-way ANOVA where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and
ns, non-significant.
Suppression Assays
1 × 105 CellTrace Violet (CTV, Thermo Fisher Scientific)-
labeled non-autologous CD4+25− (Teffs) were incubated with
or without anti-CD3/CD28 beads (at a 1:40 of bead:Teff ratio).
Co-cultures of Tregs:Teffs and Treg EVs:Teffs were set up
using varying ratios of cells and EVs, as indicated, for 5 days
at 37◦C and 5% CO2. As a control, the pellet isolated from
the same amount of media used to isolate EVs from was
used in the suppression assays. CD4+ T cell proliferation
was assessed by CTV dilution using a BD LSR-Fortessa flow
cytometer and analyzed as mentioned previously. Results are
shown as percent suppression relative to T cells cultured alone.
Culture supernatants were harvested and stored at −20◦C for
cytokine measurements.
Cytokine Measurements
Culture supernatants were analyzed using a Human
Th1/Th2/Th17 Kit BDTM Cytometric Bead Array (BD
Biosciences) according to manufacturer’s protocols. Beads
were acquired on a BD LSR-Fortessa flow cytometer
and data analyzed using FCAP Array v.3 software. IL-10
was also measured using a human IL-10 ELISA (Thermo
Fisher Scientific).
Animals and Human Skin Xenograft
Transplant Model
BALB/c recombination activating gene (RAG)2−/−γc−/− (BRG)
mice were maintained under sterile conditions (Biological
Services Unit, New Hunt’s House, King’s College London).
All procedures were performed in accordance with all legal,
ethical, and institutional requirements (PPL70/7302). Human
skin was obtained from routine surgical procedures with
informed consent and ethical approval. Skin sections (1.5 cm2)
were transplanted onto the dorsal region of 10–11 week old
BRG mice as previously described (Sagoo et al., 2011; Boardman
et al., 2017) and mice received anti-mouse Gr1 antibody
(100 ugs; BioXCell, Upper Oxfordshire, United Kingdom)
every 4 days via intraperitoneal injection. 6 weeks post-
transplant mice received 5 × 106 CD4+CD25− cells via
intravenous (IV) injection. Control mice received saline. In
addition, and concurrently, mice received 1 × 106 Tregs or
Treg-derived EVs (derived from 50 × 106 activated Tregs).
Control mice received “media EVs” (protein and EVs derived
from the EV isolation media) or saline. Transplanted human
skin was explanted for histological analysis 5 weeks post-
adoptive transfer.
Histological and Confocal Analysis
Human skin allografts explants were immediately frozen
in optimum cutting temperature (OCT) (Thermo Fisher
Scientific). Skin sections (8 µm) were fixed with 10%
formalin (Thermo Fisher Scientific) before incubating with
hematoxylin solution followed by 1% eosin (Merck). For
immunofluorescence staining, sections were fixed in 4%
paraformaldehyde, and treated with a mixture of 10% goat
serum, 0.1% fish skin gelatin, 0.1% Triton X-100 and 0.5%
Tween-20 (Merck) in PBS. Next sections were stained with
a mixture of the following primary antibodies: anti-human
CD3 (polyclonal rabbit; DAKO, Cheshire, United Kingdom)
anti-human CD45 (HI30, Thermo Fisher Scientific), anti-
human involucrin (CY5, Sigma-Aldrich), anti-human CD31
and anti-human Ki67 (both rabbit polyclonal, Abcam,
Cambridge, United Kingdom) for 18 h. Lastly, the sections
were stained with secondary antibodies goat anti-mouse Alexa
Fluor R©555 and goat anti-rabbit Alexa Fluor R©647 antibodies
with 4-6-diamidino-2-phenylindole (DAPI) (Thermo Fisher
Scientific) and mounted with Fluorescence Mounting Medium
(DAKO, Ely, United Kingdom). Nikon C2 + point scanning
confocal microscopy (Nikon, Surrey, United Kingdom) and
quantitative analysis was performed using ImageJ (FIJI)
imaging software.
MicroRNA Analysis
Total RNA was extracted from Tregs and Treg EVs as
previously described (Tung et al., 2018) and a microRNA
profile was conducted by Exiqon, United States. The EV
miRNA screen was normalized using the global normalization
method with RNU6-2 as an endogenous control. For
qPCR analysis, cDNA fragments were synthesized using
miScript RT Kit (Qiagen) and qPCR reactions were set
up with the miScript SYBR Green PCR Kit and primers
specific for miR-142-3p and miR-150-5p and RNU6-
2, as per manufacturer’s protocols (Qiagen, Hilden,
Germany). Samples were run on the Applied BiosystemsTM
ViiATM 7 Real time PCR system. Data was analyzed
using the 11CT method where RNU6-2 was used as
housekeeping controls.
Statistics
Statistical significance was determined using student’s t test,
one-way ANOVA with Tukey’s multiple comparisons test. Data
was analyzed using PRISM software (GraphPad Software, Inc,
California, United States).
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FIGURE 3 | Treg EVs modify cytokine production. CD4+25− (Teffs) cells were co-cultured alone (−) or with anti-CD3/CD28 coated beads in the absence (+) or
presence of Treg EVs derived from various numbers of Tregs (Treg EVs × 106) or different ratios of Tregs. After 5 days the presence of (A) IFNγ, (B) IL-6, (C) IL-2,
(D) IL-4, and (E) IL-10 was assessed by flow cytometry. Individual graphs (A–E) show the relevant cytokine levels produced by Teffs exposed to Tregs or Treg EVs
isolated from 7 to 9 individual donors. Each assay was performed as a technical triplicate. Data is shown as the fold change relative to activated Teffs (+), which was
set arbitrarily as 10. Statistical significance was tested using one-way ANOVA; mean ± SEM is shown where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001,
and ns, non-significant.
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RESULTS
Human Treg Cells Release Extracellular
Vesicles
Several publications from us, and others, have demonstrated
that Tregs isolated from mouse (Smyth et al., 2013; Okoye
et al., 2014) rat (Yu et al., 2013; Aiello et al., 2017) and
human (Torri et al., 2017; Azimi et al., 2018) sources can
produce EVs. To characterize human Treg EVs, CD4+CD25+
human T cells were enriched by magnetic beads separation
from healthy donor peripheral blood (average purity of
95.1 ± 3.02%, Supplementary Figures S1A,B), stimulated
with anti-CD3/CD28 beads and expanded ex vivo in the
presence of interleukin-2 (IL-2) and rapamycin, as previously
published (Scottà et al., 2013). This protocol has been used
for the expansion of Tregs for clinical application in the
treatment of renal and liver transplant patients (Romano
et al., 2017; Sánchez-Fueyo et al., 2019). The resulting cells
maintained a standard Treg phenotype (CD4+CD25hiCD127low)
with a high expression of FoxP3, CTLA-4, CD39, and CD73
(Supplementary Figures S2A,B), as previously reported (Scottà
et al., 2013; Boardman et al., 2017). Furthermore, these cells also
expressed detectable levels of common markers used to define
EVs (Théry et al., 2018) including the tetraspanin molecules
CD81, CD63, and CD9 (Supplementary Figures S2C,D).
As expected, these cells were suppressive, as determined
by their ability to inhibit CD4+25− T cell proliferation
(Supplementary Figure S2E).
To isolate EVs, and to avoid the isolation of apoptotic
bodies, Tregs were stimulated with plate bound anti-CD3/CD28
antibodies for 24 h and EVs isolated from cell supernatants.
The presence of Treg EVs with a cup-shaped morphology was
confirmed by electron microscopy (EM) (Figure 1A, left panel).
These vesicles had a mean size of 150 nm and a mode of 125 nm,
as assessed by NTA suggesting that they are small EVs (sEVs,
Figure 1A middle and right panels). Following activation, the
number of released sEVs increased significantly with an average
of 1.15 × 103 vesicles (range of 0.55 × 103−1.82 × 103 vesicles)
being released per activated Treg cell (Figure 1B).
Our previous study showed that murine Treg EVs presented
CD63, CD81, CD4, CD25, CTLA-4, and CD73 by flow cytometry
using latex beads (Smyth et al., 2013). As such, we next
characterized our human Treg EVs phenotypically (Figure 1C).
Treg EVs presented CD63 and CD81 as expected, as well as CD25,
CD39 molecules and CCR4 (Figure 1C). Low levels of CD4 and
CTLA-4 were also observed whilst in contrast, FasL and CD73
were not associated with these vesicles (Figure 1B). The presence
of CD63+ CD81+ on Treg EVs particles was confirmed using a
CD63 ExoELISA and Western blotting (Figure 1D).
In accordance with the ISEV position paper on the minimal
requirements for reporting EV data (Théry et al., 2018) we
assessed several proteins of EV and non-EV origin in our samples.
A proteomic screen of the precipitated EV rich pellet, from
one donor, was performed. HSP90AB1, actin and tubulin, all
previously shown in EVs, were observed (Figure 1E), however,
calnexin was not detected (Figure 1D). Previous studies have
shown that albumin is a major protein, of non-EV origin, co-
isolated with EVs from culture supernatants (Théry et al., 2018).
Indeed serum albumin was present in our EV sample (Figure 1E).
Taken together, activated human Tregs released small
CD63+CD81+ vesicles, which express molecules found on
their cellular equivalent, including CD25, CD39 as well as the
homing receptor CCR4.
Human Treg EVs Suppress T Cell
Proliferation in vitro
Next, we tested the suppressive capacity of human CD4+CD25+
T cell derived EVs in vitro. Cell Trace Violet R© (CTV)-labeled
CD4+CD25− Teffs were stimulated with anti-CD3/CD28 coated
beads in the presence or absence of different quantities of Treg
EVs (Figures 2A). As expected, Teff proliferation was suppressed
in the presence of Treg EVs in a dose-dependent manner with
the maximal inhibition of T cell proliferation observed in the
presence of Treg EVs isolated from 50 × 106 cells (Figures 2A).
This was constant across several different donor Treg EVs
(Figure 2B, 5 × 106 Treg-derived EVs versus 50 × 106 Treg-
derived EVs p = 0.0438; 10 × 106 Treg-derived EVs versus
50 × 106 Treg-derived EVs p = 0.0317; 35 × 106 Treg-derived
EVs versus 50× 106 Treg-derived EVs p = 0.0190).
Next, the efficiency of Treg EVs to suppress T cell proliferation
compared with Tregs was addressed. The suppression of T cell
responses observed in the presence of 50× 106 Treg-derived EVs
was equivalent to those observed when the Teff:Treg ratio was
at 1:8 (Figure 2C), suggesting that whilst Treg EVs are immune
modulatory, they are less efficient at inducing suppression than
the Treg cells themselves in the in vitro assay used. Given that
the protocol used to isolate the Treg EVs co-precipitated albumin
the contribution of this, and other non-EV proteins, to the
above observations was assessed. To do this a Treg EV free
control; “pellet” isolated from similar volumes of media used
to culture cells during activation, was included in the assays.
Importantly, no inhibition of Teff proliferation was observed
in the absence of Treg EVs (Figures 2D). Taken together, our
observations highlight the capacity of Treg-derived EVs to inhibit
Teff proliferation in vitro.
Human Treg EVs Modulate Teffs
Cytokine Production
Next, the direct modulation of Teff function by human Treg EVs
was evaluated. Teffs were stimulated with anti-CD3/CD28 beads
in the presence or absence of either Treg cells or Treg EVs and
cytokine production was evaluated. Teffs produced high levels
of IFNγ, IL-2, and IL-6, which were significantly reduced in the
presence of Treg cells in a dose dependent manner. Exposure to
Treg EVs significantly reduced IFNγ and IL-6 secretion in a dose
dependent manner (Figures 3A,B) while IL-2 was significantly
reduced following exposure to 50 × 106 Treg derived EVs only
(Figure 3C). Like the proliferation data, the reduction of these
pro-inflammatory cytokines by Treg EVs was less efficient than
those induced by their cell counterparts.
In contrast, we observed a significant increase in IL-
4 and IL-10 cytokine production in the supernatants
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FIGURE 4 | MiRNA present in Treg EVs target the 3′ UTR of mRNA of IL-2, IL-6 and IFNγ cytokines. (A) Microarray heat map diagram showing a two-way
unsupervised hierarchical clustering of miRNAs by Tregs and Treg EV miRNAs. Cells and EVs from three independent donors are shown. (B) Table of miRNAs found
exclusively in Treg EVs or enriched in Treg EVs compared to Tregs and their targeting prediction to 3′ UTR of IFNγ, IL-2 and/or IL-6 mRNA. (C). Bar graphs
(mean ± SEM) showing the relative quantity (RQ) of miR-142-3p and miR-150-5p expression in Tregs EVs and control EVs, as measured by qPCR and normalized
relative to RNU6-2. Data was pooled from 3 individual experiments that were performed in triplicates. Statistical significance was determined using an One way
ANOVA and Tukey’s multiple comparison test, where **p < 0.01 and ***p < 0.001.
of Teffs following co-culture with high doses of Treg
derived EVs (Figures 3D,E, respectively). Interestingly,
the increased level of cytokines observed were greater
than those produced in the presence of Tregs (1:1 and 1:2
Teff:Treg ratio). This increase in IL-10 was not due to this
cytokine being present in the Treg EVs themselves. No IL-
10 was detected in lysed EVs using an IL-10 specific ELISA
(data not shown).
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FIGURE 5 | Human Treg EVs protect against alloimmune mediated human skin allograft damage. BALB/c Rag2−/−γc−/− mice were transplanted with human skin
and 6 weeks later mice were reconstituted with 5 × 106 allogenic CD4+25- T cells plus polyclonal 1 × 106 Tregs or Treg EVs derived from 50 × 106 Tregs. Control
mice received saline only or control EVs (media EVs). Human skin grafts were removed 5 weeks post-injection, and cryopreserved sections were fixed and stained
for human CD45/Ki67/DAPI (A), or CD31/involucrin/DAPI (A). Representative images of human skin graft sections with the various treatments are shown.
(B) Quantification of the number of human CD45+ cells and Ki67+ keratinocytes cells per field of view was performed using NIS Elements and FIJI imaging software.
Results represent 3–9 mice per group where four to six fields of view were quantified per section and data are representative of 5 individual experiments. Statistical
significance was tested using one-way ANOVA and Turkey multiple comparison post hoc test where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns,
non-significant. DAPI, 4’,6-diamidino-2-phenylindole.
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Murine Treg EVs contain miRNAs which, when acquired,
modify the cytokine profile of the target cells (Tung et al.,
2018). To assess whether miRNAs present in our human
Treg EVs could potentially affect pro-inflammatory cytokine
production, a microarray screen was undertaken (Figure 4A).
A bioinformatics tool (microRNA.org) was used to predict
whether miRNAs highly expressed in Treg EVs, as compared
to the Tregs, targeted the 3′UTRs of IFNγ, IL-2 and IL-
6 mRNA (Supplementary Figures S3A–C). As shown in
Figure 4B, several miRNAs were identified which were predicted
to recognize one or more target sequences within each of the
aforementioned pro-inflammatory cytokine mRNAs. In addition,
two miRNAs present in murine Treg EVs, miR-142 and miR-150,
linked with reduced IL-6 (Sun et al., 2013) and IL-10 production
in DCs and T cells, respectively (King et al., 2016), were also
identified and their expression validated by qPCR (Figure 4C).
Overall, these results demonstrate that like their cell
counterparts, human Treg EVs have the capacity to skew CD4+
T cells toward an anti-inflammatory state, with Treg EVs being
more efficient at doing so than Tregs. We suggest that the
miRNAs enriched in the human Treg EVs maybe responsible for
the modulation of the cytokine profile observed, although this
requires validation. Given these findings we next tested whether
the protective effects seen in vitro could be translated in vivo.
Human Treg EVs Function in vivo
To investigate the in vivo effect of human Treg EVs, a well-
established humanized mouse model of skin transplantation was
selected (Sagoo et al., 2011; Putnam et al., 2013; Boardman
et al., 2017). In this model, human skin grafts were transplanted
onto immune deficient BALB/c Rag2−/−γc−/− mice prior
to reconstituted with allogeneic human CD4+CD25− T cells
alone or in combination with autologous Tregs or Treg EVs
(Supplementary Figure S4A). H + E staining of human
skin isolated from mice 30 days after being treated with
CD4+CD25− T cells displayed an irregular stratum corneum,
disrupted epidermis and dense cellular infiltration compared
to saline-treated control mice (Supplementary Figure S4B).
Additionally, the epidermal thickness and the rete ridge height
were significantly increased (Supplementary Figures S4C,D),
indicating an alloimmune-mediated inflammatory response
(Sagoo et al., 2011; Putnam et al., 2013; Boardman et al.,
2017). Conversely, the injection of CD4+CD25− T cells in
the presence of Treg EVs resulted in a smooth stratum
corneum as well as a significant decrease in epidermis
thickness, rete ridge height (p < 0.05) and cellular infiltration
(Supplementary Figures S4C,D).
To validate these findings, the expression of specific immune
cell and skin-related markers was assessed by three-color
immunofluorescence microscopy. As expected, compared to
saline controls, grafts from CD4+CD25− T cells treated mice
showed active inflammation with human CD3+ and CD45+
cell infiltrates (Figures 5A,B and Supplementary Figure S5)
and loss of dermo-epidermal integrity, mediated by allogeneic
human leucocytes (Figure 5A). Quantitative analysis of histology
findings demonstrated that treatment with Treg EVs, but not
proteins isolated in the media pellet, significantly decreased
the number of infiltrating human CD45+ cells (Figure 5B, left
panel), which correlated with significantly fewer CD3+ T cells
(Supplementary Figures 5A,B). In addition, Treg EV treatment
significantly decreased the frequency of Ki67+ proliferating
keratinocytes (Figure 5B, right panel). All these parameters
were reduced in skin transplants following Treg treatment, as
previously shown (Putnam et al., 2013; Boardman et al., 2017).
These results highlight the efficacy of Treg EVs in protecting
allografts in vivo and suggest that these vesicles have relevance
in clinical application to prevent graft rejection.
DISCUSSION
In this study, we show that TCR-activation of human Tregs
results in the release of small EVs capable of suppressing T cell
proliferation and altering their cytokine profile in favor of IL-
4 and IL-10 secretion. In a humanized mouse model, human
Treg-derived EVs protected human skin grafts from alloimmune-
mediated damage. Taken together, these observations suggest that
human Treg EVs are immune regulators, which may represent a
translatable therapy for the treatment of transplant rejection.
Like murine Tregs, EVs released by their human counterparts
inhibit T cell proliferation in a dose dependent manner (Smyth
et al., 2013). The exact mechanism behind this observation is
unknown, however, one possible explanation is based on the
evidence that Treg EVs express Treg-associated markers such as
CD39 and CD25. Given that both of these molecules have been
linked to the immunosuppressive nature of Tregs, it is tempting
to suggest that CD25 and CD39 expression on Treg EVs may
explain the inhibition of proliferation observed. The presence of
CD25, a high affinity receptor for IL-2, on murine Tregs and T
cell derived EVs has previously been reported (Nolte-t Hoen et al.,
2004; Smyth et al., 2013). It is tempting to speculate that CD25+
Treg derived EVs bind to the cell surface of T cells, leading
to depletion of IL-2 from the microenvironment and apoptosis
of Teffs. IL-2 was indeed reduced in the presence of high
concentrations of Treg EVs, suggesting that CD25 on Treg EVs
could be playing a similar role, driving the immunosuppressive
response, although this needs to be validated.
Ectoenzymes CD39 and CD73 present on Tregs work together
to convert pro-inflammatory ATP into anti-inflammatory
adenosine (Deaglio et al., 2007), which can be taken up
by adenosine A2 receptors to suppress target cell function
and provide an anti-inflammatory microenvironment. CD73
expression contributed directly to the suppressive nature of
mouse Treg EVs (Smyth et al., 2013), however, a similar
possibility does not exist with the human counterparts, as the
human derived EVs do not express this molecule. Although our
human Treg EVs only contained CD39, as human T cells express
A2 adenosine receptors (Koshiba et al., 1999; Ohta et al., 2009;
Linden and Cekic, 2012) it is possible that the combination of
these proteins on Teffs following Treg EV fusion resulted in the
immune suppression observed in our co-cultures.
Another possible explanation, although not mutually
exclusive, is the function of miRNAs identified within the EVs.
Recently, Torri et al. highlighted that human Treg EVs were
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highly enriched in miR-146a-5p, which suppressed proliferation
of CD4+ T cells by inhibiting Stat1 and Irak2 mRNA levels (Torri
et al., 2017). Like this study, we also observed miR-146a-5p in
Treg EVs, suggesting that this miRNA may contribute to the
reduced Teff proliferation observed.
In our study, we observed a modulation of cytokines produced
by T cells following exposure to Treg EVs. Treg EVs reduced IL-
6 whilst increasing IL-4 and IL-10 production. IL-6 is known to
work in concert with TGFβ to cause degradation of FOXP3 (Gao
et al., 2012) and promote the differentiation of pro-inflammatory
Th17 cells from naïve CD4+ T cells (Bettelli et al., 2006). In
contrast, in the absence of IL-6, naïve T cells are more prone
to commit toward a Treg compartment (Bettelli et al., 2006). As
such, by reducing the presence of detectable IL-6, it is possible
that Treg derived EVs both hinder the differentiation of Th17
cells and promote the development of immunosuppressive Tregs.
Furthermore, IL-4 is a critical factor involved in skewing naïve T
cell differentiation toward a Th2 phenotype.
It is known that EVs are carriers of cytokines (Clayton et al.,
2007; Szabó et al., 2014; Konadu et al., 2015; Tokarz et al.,
2015) it is therefore conceivable, and another way that EVs
modulate the immune response, that the presence of cytokines
such as IL-4 and IL-10 are found within the human Treg EVs
themselves. However, we have previously shown that murine
Treg EVs did not contain IL-10 (Tung et al., 2018) and confirmed
this finding with human Treg EVs. Like our current study, we
previously observed an increase of IL-10 production in LPS
activated BMDCs following treatment with murine Treg EVs,
suggesting that something intrinsic to the Treg EVs increased IL-
10, and presumably IL-4, production in recipient cells. Several
components of the Treg EVs maybe responsible for this including
miRNAs. We have recently suggested that miR-150 expressed in
murine Treg EVs altered cytokine production in LPS activated
DCs leading to an increase in IL-10 (Tung et al., 2018). Our
conclusion was based on the published findings of King et al.
(2016) who observed that miR-150 was overexpressed in IL-10
secreting CD46-induced human CD4+ T cells (King et al., 2016).
The same authors demonstrated that inhibiting miR-150, using a
miR-150 antisense locked nucleic acid (LNA), led to a decrease
in IL-10 production by these cells (King et al., 2016). In this
study, we have shown that miR-150 is present in human Treg
EVs, suggesting that it might be responsible for the modulation
of the IL-10 cytokine profile observed.
As mentioned above, IL-6 is a pro-inflammatory cytokine,
produced by many cells including T cells, which has a pleotropic
effect on cells of the innate and adaptive immune system
(Tanaka et al., 2014). This cytokine has also been shown to drive
transplant rejection with Zhao et al. (2012) demonstrating that,
with co-stimulatory blockade (CTLA-4-Ig), wild-type C57BL/6
mice rejected fully mismatched BALB/c cardiac grafts but IL-
6-deficient C57BL/6 mice accepted these allografts. The authors
suggested that blocking IL-6 production and IL-6 signaling
in combination with co-stimulatory blockade inhibited Th1
responses, and promoted transplant tolerance (Zhao et al., 2012).
Recently, the role of IL-6 in allograft rejection was revisited
(Pilat et al., 2019). These authors showed that in combination
with rapamycin and an anti-IL-2 monoclonal antibody plus
IL-2-complex, blocking IL-6 prolonged MHC mismatched skin
transplants for greater than 75 days (Pilat et al., 2019). Here, we
show that T cell derived IL-6 production was inhibited in the
presence of Treg EVs, suggesting one way that these vesicles may
have abrogate T cell alloresponses seen in our mouse model. In
addition, early work by Bushell et al. (1999) showed that IL-4
plays a role in tolerance induction to an alloantigen following
Treg transfer (Bushell et al., 1999). Therefore increasing IL-4
levels through administration of Treg EVs maybe beneficial for
transplant outcomes. Our data highlight that these vesicles could
play a protective role in the setting of transplantation. The novel
finding that human Tregs EVs prevented alloimmune-mediated
damage in human skin allografts, following administration,
highlights their potential as a novel cell-free therapy for
inhibiting inflammation. The inhibition of IL-6, together with the
modulation of IL-4, further underlines the potential of Treg EVs
as immunotherapy reagents for transplant patients.
In summary, human Treg EVs inhibit T cell proliferation
and cytokine production in vitro and protect human skin
grafts from alloimmune-mediated damage in vivo. Given
the latter, and as we previously suggested (Agarwal et al.,
2014), these vesicles have the potential to be translated into
the clinic as a stand-alone personalized therapy. One major
development, that will help the translation of Treg EVs
into the clinic, is the recent publication of data from a
phase 1 clinical trial on the efficacy of autologous human
Tregs in a liver transplant setting (Sánchez-Fueyo et al.,
2019). These authors highlighted that administration of these
cells to patients post-transplant was safe and led to a
transient increased in Treg numbers whilst decreasing CD8+
donor-specific responses over time following injection, hence
demonstrating efficacy. These important findings align with
our speculation that Treg EVs may have a similar effect to
their cellular counterparts in vivo. Given that these authors
found no adverse affects with Tregs helps pave the way for
their EVs to be used in a similar setting. Whether these
vesicles are best used in combination with Tregs cells has yet
to be addressed.
In our previous review we discussed several hurdles that
required addressing before human Treg EVs could be used
in a clinical setting. These included designing protocols for
optimizing ex vivo isolation of GMP-grade Treg EVs, improving
scalability and assessing reproducibility, a full assessment of
protein contaminants, identification of in vivo targets as well
as working out a dosing regime. Although many of these
are still relevant we feel that our protocol of EV isolation
allows reproducibility, as determined by the consistency in EV
miRNAs expression across several donors. Since the publication
of our review several key advances such as GMP compatible EV
isolation reagents, bioreactors to allow scalability and tangential
flow filtration (Busatto et al., 2018) are transforming EVs
research, with several companies now attempting to create off the
shelf EV products for patient use. Given this, and the fact that
DC-derived EVs have been used in phase II clinical trials for the
treatment of non-small cell lung cancer, and were found to have
efficacy (Besse et al., 2016, achieving a similar outcome for Treg
EVs within liver or kidney transplantation maybe feasible.
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